LABORATORIOS FARMACEUTICOS ROVI S.A financials
LABORATORIOS FARMACEUTICOS ROVI S.A
Country: ES Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
95980020140005936480 Financial statements
(EUR, as reported — unscaled; 110 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €763.7M | €829.5M |
| Employee benefits expense | €135.7M | €122.8M |
| Raw materials & consumables used | €343.9M | €359.6M |
| Depreciation & amortisation | €28.0M | €24.3M |
| Operating profit (EBIT) | €179.5M | €220.3M |
| Net finance income / (cost) | -€1.7M | €279.0K |
| Finance costs | €2.4M | €948.0K |
| Profit before tax | €177.7M | €220.4M |
| Income tax expense | €40.8M | €50.1M |
| Profit for the year | €136.9M | €170.3M |
| — attributable to owners | €136.9M | €170.3M |
| — attributable to NCI | -€5.0K | -€36.0K |
| Total comprehensive income | €136.9M | €170.3M |
| Per share | ||
| Basic EPS | €2.67 | €3.20 |
| Diluted EPS | €2.67 | €3.20 |
| Free cash flow / share | €1.54 | €1.12 |
| Cash flow statement | ||
| Net cash from operating activities | €138.3M | €113.2M |
| Net cash from investing activities | -€81.1M | -€52.0M |
| Purchase of PP&E (capex) | €59.1M | €53.8M |
| Purchase of intangibles | €3.1M | €1.4M |
| Net cash from financing activities | -€55.4M | -€160.8M |
| Dividends paid | €56.5M | €69.0M |
| Proceeds from borrowings | €97.0M | €734.0K |
| Repayments of borrowings | €51.7M | €13.7M |
| Balance sheet | ||
| Total assets | €832.0M | €799.9M |
| Non-current assets | €342.4M | €290.6M |
| Property, plant & equipment | €286.6M | €253.7M |
| Current assets | €489.6M | €509.3M |
| Inventories | €330.0M | €338.0M |
| Trade & other receivables | €129.5M | €143.3M |
| Cash & equivalents | €27.2M | €25.3M |
| Total equity | €581.5M | €543.5M |
| — attributable to owners | €572.0M | €539.4M |
| Non-controlling interests | €9.5M | €4.1M |
| Non-current liabilities | €93.8M | €56.5M |
| Long-term borrowings | €90.7M | €52.2M |
| Current liabilities | €156.7M | €199.8M |
| Trade & other payables | €125.3M | €141.9M |
| Deferred tax liabilities | €366.0K | €1.5M |
| Derived metrics | ||
| Free cash flow | €79.2M | €59.5M |
| Operating margin | 23.5% | 26.6% |
| Net margin | 17.9% | 20.5% |
| Return on equity | 23.5% | 31.3% |
| Cash conversion ratio | 1.01× | 0.67× |
| Capex coverage | 2.34× | 2.11× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | -€23.0K | -€21.0K |
| Adjustments For Decrease Increase In Inventories | €11.9M | -€29.3M |
| Adjustments For Decrease Increase In Other Current Assets | €40.0K | -€702.0K |
| Adjustments For Decrease Increase In Trade and Other Receivables | €13.4M | €19.5M |
| Adjustments For Depreciation and Amortisation Expense | €28.0M | €24.3M |
| Adjustments For Finance Costs | €2.4M | €948.0K |
| Adjustments For Finance Income | €259.0K | €1.5M |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | €0 | -€28.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | -€4.1M | €3.2M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€16.4M | -€23.9M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €141.0K | €125.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€296.0K | €86.0K |
| Changes In Inventories of Finished Goods and Work In Progress | -€57.9M | -€18.6M |
| Comprehensive Income Attributable To Noncontrolling Interests | -€5.0K | -€36.0K |
| Comprehensive Income Attributable To Owners of Parent | €136.9M | €170.3M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €23.7M | €13.2M |
| Current Contract Liabilities | €4.8M | €39.0M |
| Current Deferred Income Other Than Current Contract Liabilities | €445.0K | €464.0K |
| Current Financial Assets At Amortised Cost | €227.0K | €0 |
| Current Prepaid Expenses | €2.7M | €2.7M |
| Current Tax Assets Current | €81.0K | €0 |
| Current Tax Liabilities Current | €2.4M | €5.3M |
| Deferred Tax Assets | €2.3M | €2.3M |
| Dividends Recognised As Distributions To Owners Per Share | €1.10 | — |
| Equity and Liabilities | €832.0M | €799.9M |
| Finance Income | €259.0K | €1.5M |
| Gains Losses On Exchange Differences On Translation Before Tax | -€2.0K | -€18.0K |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | €296.0K | -€86.0K |
| Gains Losses On Financial Assets Measured At Fair Value Through Other Comprehensive Income Net of Tax | €0 | €7.0K |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €0 | €2.0K |
| Income Taxes Paid Refund Classified As Operating Activities | -€44.2M | -€40.9M |
| Increase Decrease In Cash and Cash Equivalents | €1.9M | -€99.6M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Change In Equity of Subsidiaries | -€5.4M | -€2.8M |
| Increase Decrease Through Transfers and Other Changes Equity | — | -€637.0K |
| Intangible Assets Other Than Goodwill | €34.0M | €33.9M |
| Interest Paid Classified As Financing Activities | €1.8M | €388.0K |
| Interest Received Classified As Investing Activities | €134.0K | €1.5M |
| Investment Accounted For Using Equity Method | €19.5M | €567.0K |
| Issued Capital | €3.1M | €3.2M |
| Liabilities | €250.5M | €256.4M |
| Losses On Disposals of Property Plant and Equipment | €4.4M | €0 |
| Miscellaneous Other Operating Expense | €136.0M | €125.7M |
| Noncurrent Contract Liabilities | €1.8M | €1.4M |
| Noncurrent Deferred Income Other Than Noncurrent Contract Liabilities | €927.0K | €1.4M |
| Noncurrent Investments In Equity Instruments Designated At Fair Value Through Other Comprehensive Income | €0 | €24.0K |
| Noncurrent Receivables | €65.0K | €65.0K |
| Other Comprehensive Income | -€2.0K | -€13.0K |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€2.0K | -€13.0K |
| Other Work Performed By Entity and Capitalised | €648.0K | €3.9M |
| Payments To Acquire Or Redeem Entitys Shares | €89.7M | €133.9M |
| Proceeds From Issuing Other Equity Instruments | €5.4M | €2.8M |
| Proceeds From Sale Or Issue of Treasury Shares | €41.9M | €52.6M |
| Proceeds From Sales of Investments Accounted For Using Equity Method | €0 | €1.8M |
| Proceeds From Sales of Investments Other Than Investments Accounted For Using Equity Method | €80.0K | €88.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €37.0K | €382.0K |
| Purchase of Interests In Investments Accounted For Using Equity Method | €19.1M | €600.0K |
| Purchase of Treasury Shares | €89.7M | €133.9M |
| Reduction of Issued Capital | €0 | — |
| Revenue From Government Grants | €840.0K | €781.0K |
| Sale Or Issue of Treasury Shares | €41.9M | €52.6M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -€141.0K | -€125.0K |
| Share Premium | €87.6M | €87.6M |
| Statutory Reserve | €673.0K | €673.0K |
| Treasury Shares | €5.5M | €107.7M |
Methodology
Every line item above is a fact tagged in LABORATORIOS FARMACEUTICOS ROVI S.A's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.